AstraZeneca Regulatory Update on Seroquel XR for the Treatment of Major Depressive Disorder
- Details
- Category: AstraZeneca
AstraZeneca today announced that the company has referred its application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of recurrent depressive episodes in adult patients with major depressive disorder (MDD) to the Committee for Medicinal Products for Human Use (CHMP; a scientific committee of the European Medicines Agency, EMEA).
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva®
- Details
- Category: Bayer
Bayer HealthCare AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Roche announced the initiation of a Phase III trial examining Nexavar® (sorafenib) tablets in combination with Tarceva® (erlotinib) tablets as a potential new treatment option for
patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
Nycomed Reports a Solid Start to 2009
- Details
- Category: Nycomed
Nycomed reports a solid start to 2009, with total net turnover increasing by 1.2% to €839.9 million, despite adverse impact from currency movements. Excluding the effects of currency, the increase was 3.8%, underlining the solid performance of the main product Pantoprazole and other key products. On a regional basis, most Nycomed markets performed in line with or above expectations.
US Department of Health and Human Services (HHS) purchases GSK's A (H1N1) influenza antigen
- Details
- Category: GlaxoSmithKline
The US Department of Health and Human Services (HHS) has placed initial orders for GSK's A (H1N1) influenza vaccine antigen and the company's proprietary adjuvant system, AS03, to support its pandemic influenza preparation efforts.
Roche announces new two-year data from the LITHE study
- Details
- Category: Roche
Roche has announced that new two-year data from the LITHE study(1) demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) continues to be highly effective at inhibiting joint structural damage and maintaining consistently high remission rates. Reducing the structural damage to joints in patients with rheumatoid arthritis (RA) is a critical measure of effectiveness of an RA treatment.
Sandoz to acquire EBEWE Pharma specialty generics business
- Details
- Category: Novartis
Novartis has signed a definitive agreement to acquire the specialty generic injectables business of EBEWE Pharma, providing Sandoz - the Group's generic pharmaceuticals division - an opportunity to create a strong global platform for future growth while improving access for patients worldwide to many generic oncology medicines.
Abbott's XIENCE V(R) Demonstrates Impressive Results in SPIRIT V Study
- Details
- Category: Abbott
New data presented at EuroPCR from an international, post-approval, single-arm study show that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated low rates of repeat procedure (target lesion revascularization), stent thrombosis and major adverse cardiac events (MACE) in a complex patient population.
More Pharma News ...
- Pfizer Expands Its Generics Portfolio
- Sanofi-aventis introduces sanofi-aventis TV "A window on our company"
- Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
- Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management
- New data to be presented on Abbott's market-leading XIENCE V(R) stent
- GlaxoSmithKline update: A (H1N1) influenza vaccine development
- Novartis receives approval from FDA to market Prevacid®